State Board of Pharmacy advances compounding regulation package to 15-day comment period after hours-long debate

The California State Board of Pharmacy on Jan. 8 approved moving a package of revised compounding regulations to a 15-day public comment period, following hours of staff briefings, board discussion and more than two dozen public comments from hospitals, pharmacists, patient advocates and associations.

The package, which the board referred to as a set of second/third modified texts, would reorganize and update numerous California Code of Regulations sections (including proposed changes to sections 1735, 1736, 1737 and 1738) to align state rules with federal law and United States Pharmacopeia (USP) compounding chapters while preserving higher California patient-safety standards where they exist. President Sung Oh said the board’s mandate requires it to prioritize public protection. "The board is a consumer protection agency charged with administering and enforcing pharmacy law," he said.

Why it matters: the changes address a wide range of compounding practices — nonsterile and sterile compounding, hazardous-drug handling, radiopharmaceuticals and limited flavoring exemptions — and include provisions stakeholders said could affect access to medications for hospitalized patients, veterinary patients, and populations using compounded products (including firefighters and some patients seeking nebulized or IV therapies). Some commenters urged broader exemptions or clearer paths for specific products; others warned that certain requirements would raise costs or reduce access.

What the board approved and delegated

Maria (board member) moved that the board accept staff responses to comments received during the 30-day comment period, approve the recommended modified text for a 15-day comment period as directed by the board, and delegate authority to members Serpa and Barker (and the Enforcement and Compounding Committee chair working with staff) to review additional comments and recommend actions to the full board. The motion was seconded and carried unanimously by roll call vote. The official action recorded: approved and sent the package out for a 15-day comment period and delegated review authority to committee members; outcome: approved.

Major substantive points discussed

- Nonsterile compounding (proposed section 1735): staff recommended clarifications to "essentially a copy" language to require a pharmacist to verify and document clinical significance when a product would otherwise duplicate a commercially available drug. The text would allow some flexibility for veterinary supplies (a recommended increase to a 14-day supply for veterinary patients) and would add a new section specifically dealing with flavoring agents to permit pharmacists to add flavoring under specified conditions without prescriber consultation while requiring facilities to adopt standard operating procedures (SOPs) documenting how they will meet safety requirements.

- Sterile compounding (proposed section 1736): staff described several updates intended to give facilities greater operational flexibility while preserving patient-safety controls. Notable recommendations include immediate-use allowances for certain failures (expanded from a 24-hour allowance to 48 hours in many cases, with a longer 120-hour allowance proposed for critical access hospitals under specified conditions and after attempts to remediate under facility SOPs are unsuccessful) and a recommendation to extend some veterinary sterile-supply limits to seven days.

- Hazardous drugs (proposed section 1737): the draft clarifies which manipulations of antineoplastic hazardous drugs are covered (for example, crushing or splitting tablets or opening capsules), emphasizes alignment with Cal/OSHA (Title 8) and USP 800 practices, and proposes labeling and glove-use flexibilities in some controlled circumstances (such as preparing multiple HD preparations for a single patient).

- Radiopharmaceuticals (proposed article 4.8 / section 1738): staff recommended aligning notification timing and removing redundant prohibitions already covered elsewhere in the chapter; board staff proposed changing required notification to the board from 72 hours to 96 hours in some instances.

Public comment highlights

More than two dozen people and organizations spoke or submitted comments during the meeting. Themes included:

- Patient advocates and some practitioners expressed alarm that restrictive language or enforcement had already limited patient access to certain compounded therapies (notably nebulized or intravenous glutathione and specific methylcobalamin preparations). Several patient speakers and nonprofit advocates said those therapies were clinically beneficial and urged clearer, practicable pathways to restore access.

- Hospital systems and large health-care providers (including speakers from UC San Diego Health, UCHealth and Scripps Health) urged wider immediate-use allowances and operational flexibility for equipment or facility failures. UCHealth and other hospital commenters sought a longer allowance in some failure scenarios (one asked for up to seven business days in limited circumstances); board staff and members said 48 hours (and up to 120 hours for critical access hospitals under specified remediation conditions) was the compromise adopted for the draft sent to the 15-day comment period.

- The California Medical Association and other medical-practice representatives asked for explicit clarifying language to make clear that the board’s regulations do not apply to physicians’ compounding done under the jurisdiction of other healing-arts boards. CMA asked the board to adopt explicit exemption language; CMA’s representative said the absence of such a statement risks misapplication of pharmacist-centric requirements to medical-office practice.

- Industry commenters raised cost and operational concerns, arguing that some proposed requirements (for example, frequent replacement of sterile ASTM D6978 gloves between every hazardous-drug preparation) would impose large, unaccounted-for costs and workflow burdens. Kaiser Permanente’s comment estimated substantial annual statewide costs if some glove-change provisions were kept.

Board members and staff responses

Board staff repeatedly told members and the public that the draft package aims to align state regulation to federal law and USP standards while maintaining California’s higher existing safeguards where present. Maria, who led the staff presentation and later moved the motion, said the package was intended to provide clarity and a path forward for licensees that have been operating amid confusing transitions since USP updates in 2022–23.

Multiple board members pressed staff to: add clarifying language about remediation steps and remediation-triggered immediate-use provisions; ensure flavoring exemptions are narrowly drawn for facilities that only add flavoring and not other compounding; and refine language about adverse-drug-experience reporting so it would not be construed as requiring reporting of ordinary side effects. The board asked staff and counsel to tidy minor typographical and cross-reference issues before issuing the 15-day notice.

Votes at a glance

- Motion: Accept staff responses to comments; approve modified rule text for a 15-day comment period; delegate to members Serpa and Barker and the Enforcement and Compounding Committee chair to work with staff on technical, non-substantive changes and on review of any new comments. Mover: Maria (board member). Second: KK (board member). Vote: Passed (unanimous roll call).

What’s next

The board will publish the directed modified text for a 15-day public comment period. Staff and the delegated committee members will review any new comments submitted in that window and report back to the full board with recommended next steps. Board staff said the objective is to finalize rules that are consistent with federal law and USP while minimizing confusion among California licensees; several board members emphasized the need to keep the record clear about which provisions are federal/USP duplications and which are California-specific additions.

Ending note: the package remains subject to further change. Several stakeholders asked the board to amend specific provisions (physician/veterinary exemptions, glove and mat-change rules for hazardous drug handling, pass-through and building-code cross-references, and immediate-use allowances for sterile compounding). Those issues are likely to reappear in written comments during the 15-day review and in subsequent board discussion.